A global ledger of negative results and failed compounds with mandatory deposition
Every failed cancer drug, experiment and trial gets recorded in one open ledger, so nobody repeats a failure that has already cost years and millions.
Most preclinical negatives are never published, most discontinued compounds vanish with their data, and terminated trials often report nothing. The proposal is a ledger with structured entries (target, compound, model, endpoint, result, reason for stopping) required as a condition of public funding, journal publication and regulatory submission, with a safe harbour for industry deposition of discontinued asset data, and incentives (citations, credit) for negative-result deposition. Discontinued compounds with clean safety could be listed for repurposing.
- Failures are hidden · Negative trials, failed drugs and abandoned programmes are rarely published, so the same mistakes are repeated.
- Preclinical results do not reproduce · Fewer than half of landmark cancer biology findings reproduce when someone else tries.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
Pages like this
not linked directly; found by shared links- IdeaEnforce individual participant data sharing as a condition of publication and funding
Shares Secrecy and intellectual property block collaboration, Preclinical results do not reproduce.
- IdeaPre-registration and results reporting for real-world cancer studies
Shares Preclinical results do not reproduce, Failures are hidden.
- IdeaA home for the animal and organoid experiments that failed
Shares Preclinical results do not reproduce, Failures are hidden.
- IdeaPre-register animal efficacy studies like clinical trials
Shares Preclinical results do not reproduce, Failures are hidden.
- IdeaLiving systematic reviews of animal and organoid evidence before every new trial
Shares Preclinical results do not reproduce, Failures are hidden.
- IdeaScoop protection and co-publication norms to reduce academic secrecy
Shares Secrecy and intellectual property block collaboration, Preclinical results do not reproduce.
- IdeaA public registry of stalled academic assets and shelved company compounds
Shares Secrecy and intellectual property block collaboration, Failures are hidden.
- IdeaBounties for documented failed replications of high-impact findings
Shares Preclinical results do not reproduce, Failures are hidden.